



Conatus Pharmaceuticals  
Investor Relations Department  
16745 W. Bernardo Drive  
Ste 200  
San Diego, CA 92127  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: CNAT**

Last Trade:	5.01
Trade Time:	4:00 PM ET Oct 19, 2017
Change:	-0.14 <span style="color: red;">↓</span> (-2.718%)
Day Range	5.00 - 5.43
52-Week Range	1.45 - 9.40
Volume	649,815

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Stock Performance



## Press Releases [\[ View all \]](#)

Oct 18, 2017

[EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC](#)

Aug 31, 2017

[Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer](#)

Aug 29, 2017

[Conatus to Present at Rodman & Renshaw Global Investment Conference](#)

Aug 14, 2017

[Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis](#)

Aug 2, 2017

[Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)